Gilead Working 24/7 To Fix Manufacturing Problems In HIV “Complete Response” Letters
This article was originally published in The Pink Sheet Daily
Executive Summary
In its first quarter earnings call, Gilead says it’s been working around the clock to address manufacturing issues that blocked FDA approval of two individual drugs in the approved Stribild HIV combination pill, problems that also affect other marketed drugs. But rising star HCV drug sofosbuvir won’t be affected, company says.
You may also be interested in...
The New Quad: FDA Approves Gilead’s 4-In-1 HIV Pill Stribild
With cost concerns already arising, the sponsor says it is working to ensure the drug is covered by state AIDS Drug Assistance Programs.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Rare Disease Roundtable: How Rare Is Too Rare?
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: